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In receptor-coupled signaling, the phenomenon called transactivation develops when one or more 
receptors activate yet another. This process has been demonstrated most exhaustively in relation to G-
protein coupled receptors (GPRCs) (1) when, upon appropriate stimuli, engagement of given GPRCs 
may cause the transactivation of other receptor signaling systems. Importantly, certain cytokines, 
chemokines and agonists of receptor tyrosine kinases (RTKs) may also exert similar effects (2). Among 
these, the epidermal growth factor receptor (EGFR) family, a key signal transduction system in skin 
biology, constitutes one of the most well-documented targets of the process. 
 
EGFR signaling is indispensable for controlling survival, migration, and proliferation of epidermal 
keratinocytes (3, 4). Activation of EGFR induces pro-survival programs and protects from apoptosis which 
processes are equally important in wound healing and hyperproliferative skin diseases (5, s1, s2). In vitro 
cell culture experiments have proven that this pathway is responsible for the autonomous replicative 
capacity of keratinocytes, as EGFR inhibitors block their proliferation (s3). Another key process of wound 
healing is the migration of keratinocytes to the wound site, which is greatly increased by EGFR ligands 
(s4). Wounding typically causes the release of membrane bound EGFR ligands and, furthermore, the 
sustained production of matrix metalloproteinase MMP-1 which is required for migration in the absence 
of the basal membrane (s5). Interestingly all of these effects may be induced not only by ligands of EGFR, 
but also by activators of other GPCRs and RTKs that subsequently activate EGFR via ligand-dependent 
or -independent mechanisms - collectively referred to as transactivation. 
 
EGFR transactivation takes place when GPCR or RTK ligands either cause the release of enzymes that 
cleave the mature forms of EGFR ligands from the cell membrane or initiate kinase cascades that result 
in the ligand-independent activation of EGFR. Ligand-dependent transactivation of EGFR has been 
proven to be instrumental in both normal cell functions [e.g. migration of smooth muscle cells (s6)] and 
disease states [breast cancer (s7) prostate cancer: (s8), reviewed in (s9) and (6)]. Ligand-independent 
activation, while also reported, is less well defined and investigated, with much more significant gaps in 
our knowledge in this regard (7).  
 
A paper by Matus et al. in a recent volume of Experimental Dermatology (8) assessed the role of EGFR 
transactivation subsequent to the engagement bradykinin receptor B1 (BRDKRB1), a GPCR that is 
expressed in keratinocytes during wound healing. In this work, the authors present compelling evidence 
that, in both in vivo or in vitro models, although the proliferation of keratinocytes was unaffected, wound 
healing was nonetheless improved upon BRDKB1 activation. The mechanism behind the enhanced 
wound closure is most likely the increased production and secretion of MMP-2 and 9 from keratinocytes 
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as well as a direct effect on keratinocyte migration. These results coincide with previous reports on MMP 
function, where these proteins were shown to inhibit proliferation and promote differentiation and survival 
(s10, s11). As presented in the paper, secretion of MMPs is initiated both by ligand dependent and 
independent transactivation of EGFR signaling. Namely, BRDKRB1 stimulation induced the production 
of ADAM17, which leads to the shedding of membrane-bound ligands. In parallel to the ligand-dependent 
transactivation of the system, the engagement of intracellular Src kinases directly phosphorylates 
intracellular sites on EGFR which leads to ligand-independent activation of the receptor.  
 
Based on these results, the bradykinin system now joins the family of GPCRs that converge on EGFR 
via ligand-dependent and/or independent transactivation. Other notable mediators that result in similar 
transactivation include, among others, acetylcholine, catecholamines, angiotensin II, endothelin-1, 
lysophosphatidic acid and thrombin (7). Although these mediators have been described to be present in 
acute wounds and evidence points to their capability of transactivating EGFR, their actual role on wound 
healing is surprisingly diverse. For example, acetylcholine – which influences adhesion, migration, 
proliferation and differentiation of keratinocytes via initiating muscarinic M1 and M3 receptor coupled 
MAP kinase activation through EGF transactivation – is generally considered to facilitate wound closure, 
while adrenergic signaling, which activates EGFR through both ligand dependent and independent 
pathways, is in general detrimental to wound healing (s12, s13). Other mediators released from wound 
sites that are capable of transactivating EGFR include angiotensin II, which causes induction of cell 
migration via autocrine transforming growth factor β signaling. Further, thrombin influences multiple 
cellular processes in the skin by activating proteinase activated receptors; however, overall it was shown 
to inhibit wound healing in vivo (s14). Whether this effect is dependent on EGFR transactivation in skin 
is uncovered to date, but since MMP expression and EGFR transactivation has been demonstrated on 
multiple cell types [including but not limited to osteoblasts, cardiomyocytes, vascular smooth muscle cells 
and lung adenocarcinoma cells; (9)] it is quite probable that it is present here as well.  
 
Based on the wide variety of activators and pathways that are capable of ultimately also acting through 
the EGFR pathway and, furthermore, the diverse responses initiated by these activators, EGFR can be 
regarded as a cellular integrator switchboard of cutaneous metabotropic receptor coupled signaling. 
Although these results collectively expand the family of EGFR ligands, the role of transactivation in a 
clinical setting is still not determined and invites further research into this exciting field. 
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